Urinary 8-iso-Prostaglandin F 2 as a Risk Marker in Patients With Coronary Heart Disease. A Matched Case-Control Study
|
|
- Beverley Lawson
- 5 years ago
- Views:
Transcription
1 Urinary 8-iso-Prostaglandin F 2 as a Risk Marker in Patients With Coronary Heart Disease A Matched Case-Control Study Edzard Schwedhelm, PhD; Asja Bartling, MD; Henrike Lenzen, MD; Dimitrios Tsikas, PhD; Renke Maas, MD; Jens Brümmer, MD; Frank-Mathias Gutzki, Ing Chem; Jürgen Berger, PhD; Jürgen C. Frölich, MD, FRSM; Rainer H. Böger, MD Background Oxidative stress is involved in the pathophysiology of atherosclerosis, diabetes mellitus, hypertension, obesity, and cigarette smoking, all of these being risk factors for coronary heart disease (CHD). We tested the hypothesis that risk factors of CHD are associated with abundant systemic oxidative stress. Methods and Results We conducted a case-control study with 93 CHD patients and 93 control subjects frequencymatched by age and sex. Urinary excretion of the F 2 -isoprostane 8-iso-prostaglandin (PG) F 2 and its major urinary metabolite, 2,3-dinor-5,6-dihydro-8-iso-PGF 2, were measured by gas chromatography tandem mass spectrometry. Body mass index, systolic blood pressure, and C-reactive protein were elevated in CHD patients (P 0.01). Urinary 8-iso-PGF 2 and 2,3-dinor-5,6-dihydro-8-iso-PGF 2 also differed, from 77 (interquartile range, ) to 139 (93 231) pmol/mmol creatinine and from 120 (91 151) to 193 ( ) pmol/mmol in control subjects and case subjects, respectively (P 0.001). 8-iso-PGF 2 and its metabolite were highly correlated (Spearman s 0.664, P 0.001). HDL cholesterol was diminished in CHD patients (P 0.001). All of these characteristics predicted CHD in univariate analysis. In a multivariate model, the odds ratios were increased only for 8-iso-PGF 2 ( 131 pmol/mmol, P 0.001) and C-reactive protein ( 3 mg/l, P 0.01), ie, by 30.8 (95% CI, ) and 7.2 ( ), respectively. 8-iso-PGF 2 was found to be a novel marker in addition to known risk factors of CHD, ie, diabetes mellitus, hypercholesterolemia, hypertension, and smoking. Urinary excretion of 8-iso-PGF 2 correlated with the number of risk factors for all subjects (P for trend). Conclusions 8-iso-PGF 2 is a sensitive and independent risk marker of CHD. (Circulation. 2004;109: ) Key Words: prostaglandins coronary disease C-reactive protein isoprostanes risk factors The past decades have shown that oxidative stress is one fundamental of pathogenesis. This covers conditions as diverse as cancer, inflammation, neurodegenerative diseases, and aging. Likewise, oxidative damage is involved in the pathogenesis of atherosclerosis and cardiovascular disease. 1,2 For many years, investigations in the field of oxidative stress were limited by a confusing number of surrogate markers with clinical relevance open to question. Reliable quantitative indices of free radical induced modification of DNA, proteins, and lipids in vivo have emerged only recently. 3,4 In the cardiovascular system, lipids are in the first line of radical attack. Morrow et al 5 have identified isoprostanes as end products of lipid peroxidation. Isoprostanes are chemically stable and can be measured noninvasively in human urine by mass spectrometry. A growing body of evidence has been provided by several groups underlining the validity of the isoprostanes as in vivo markers of oxidative stress. 3,6,7 Studies have suggested isoprostanes as markers for patients at risk of atherosclerosis and coronary heart disease (CHD): elevated isoprostane formation was found in underlying diseases such as diabetes mellitus, 8 hypertension and renovascular disease, 9 hyperlipidemia, 10 obesity, 11 and cigarette smoking. 12 The major risk factors for CHD are elevated blood pressure, elevated total cholesterol, LDL cholesterol, HDL cholesterol, diabetes mellitus, obesity, cigarette smoking, and Received September 24, 2003; revision received November 7, 2003; accepted November 18, From the Clinical Pharmacology Unit, Institute of Experimental and Clinical Pharmacology (E.S., R.M., R.H.B.), Institute of Clinical Chemistry (J. Brümmer), and Institute of Mathematics and Data Processing in Medicine (J. Berger), University Hospital Hamburg-Eppendorf, and the Institute of Clinical Pharmacology (A.B., H.L., D.T., F.-M.G., J.C.F.), Hannover Medical School, Germany. E. Schwedhelm was responsible for the methodology of isoprostane measurement, interpretation of data, and writing the report. A. Bartling and H. Lenzen were responsible for patient recruiting and organization of urine and plasma analysis. D. Tsikas and F.-M. Gutzki were responsible for the isoprostane measurement. R. Mass did data analysis and interpretation. J. Brümmer performed C-reactive protein analysis. J. Berger was responsible for statistical analysis and interpretation of data. J.C. Frölich and R.H. Böger designed and organized the study. Correspondence to Dr rer nat Edzard Schwedhelm, Institut für Experimentelle und Klinische Pharmakologie, Universitätsklinikum Hamburg- Eppendorf, Martinistraße 52, D Hamburg, Germany. schwedhelm@uke.uni-hamburg.de 2004 American Heart Association, Inc. Circulation is available at DOI: /01.CIR
2 844 Circulation February 24, 2004 advancing age. 13 Studies evaluating the quantitative relationships between these risks have elucidated their additive nature in predicting CHD. The relative magnitude at which markers of oxidative stress such as isoprostanes contribute to these risk factors is as yet unknown. In addition, the extent to which oxidative stress contributes independently to hypertension, diabetes mellitus, hyperlipidemia, and obesity is open to question. Finally, increasing oxidative stress from different clinical conditions would be expected to contribute to CHD in a cumulative manner. To evaluate the hypothesis that isoprostanes are independent and cumulative risk markers of CHD, we conducted a case-control study. Ninety-three patients with a confirmed diagnosis of CHD were included and frequency-matched by age and sex with control subjects (controls) from the general population. The isoprostanes 8-iso-prostaglandin (PG) F 2 and 2,3-dinor-5,6-dihydro-8-iso-PGF 2 were measured by gas chromatography tandem mass spectrometry (GC-tandem MS) along with C-reactive protein (CRP), oxidized LDL, and further biochemical parameters. Methods Patients and Study Protocol Patients between 35 and 80 years old with established coronary artery disease were recruited for this study. Patients were included if they had stable angina pectoris or a history of myocardial infarction, plus diagnostic criteria for recurrent myocardial ischemia (positive exercise ECG, evidence for myocardial ischemia in thallium scintigraphy, documentation of coronary stenosis by coronary angiography). Age- and sex-matched healthy controls were recruited from the general population via local newspaper advertisement. They were included in the study if they had no clinical or diagnostic evidence for coronary artery disease. Patients or controls suffering from any concomitant acute or chronic severe disease, from renal failure (creatinine clearance 30 ml/min) or hepatic insufficiency, severe chronic heart failure (NYHA functional class III or above), acute occlusive cardiovascular events (ie, within the previous 30 days before inclusion into the study), or 80 years old were excluded from the study. We assessed eligibility, obtained informed consent, and included 93 patients and 93 controls in the study. The study protocol was approved by the local Institutional Review Board for Studies in Humans. All patients and controls were invited to the study center in the morning. The patients were asked for their previous medical history and the presence of cardiovascular risk factors by use of a standardized questionnaire. A fasting blood sample was drawn, and a urine sample was collected into a vial containing 5 mmol/l 4-hydroxy- 2,2,6,6-tetramethylpiperidine 1-oxyl (4-hydroxy-TEMPO) and 5 mmol/l EDTA as antioxidants. Blood samples were centrifuged (2000g, 10 minutes, 4 C), and plasma was divided into aliquots and stored at 20 C until analysis. Urine samples were divided into aliquots and kept frozen at 80 C until analysis. Diurnal variation of creatinine-indexed isoprostane excretion was assessed in 3 subjects. No divergence was found between morning urine samples and 24-hour urine samples. 14 Therefore, we decided to collect morning urine samples instead of 24-hour collection. Biochemical Analyses Urinary concentrations of 8-iso-PGF 2 and 2,3-dinor-5,6-dihydro-8- iso-pgf 2 were determined by GC-tandem MS as described previously in detail. 15 Briefly, urine samples were thawed, and labeled internal standards of 8-iso-PGF 2 and 2,3-dinor-5,6-dihydro-8-iso- PGF 2 were added at 1 ng/ml, solid-phase-extracted on ODS, and subjected to thin-layer chromatography on silica gel. Transitions from m/z 569 to m/z 299 and from m/z 543 to m/z 273 were monitored for 8-iso-PGF 2 and 2,3-dinor-5,6-dihydro-8-iso-PGF 2, respectively, by GC-tandem MS. Validity of the method was proven as reported previously. 16 Urinary concentrations of 8-iso-PGF 2 and 2,3-dinor-5,6-dihydro-8-iso-PGF 2 were corrected by urinary creatinine concentration to account for differences in renal excretory function. Plasma concentration of oxidized LDL cholesterol was determined with a commercially available immunoassay (Mercodia SA). Plasma concentration of CRP was measured by a highsensitivity assay (N Latex Mono test) on a Behring BN II nephelometer with polystyrene microbeads coated with monoclonal mouse antibodies. 17 The detection limit of the assay was 0.2 mg/l. Plasma total cholesterol, LDL and HDL cholesterol, and triglyceride levels as well as plasma and urinary creatinine concentrations were determined by standard laboratory methods using certified assays in the local clinical laboratory. Calculations and Statistical Methods All data were tested for normal distribution with the Kolmogorov- Smirnov test. The distribution of 8-iso-PGF 2, 2,3-dinor-5,6-dihydro- 8-iso-PGF 2, and CRP was highly skewed, as reported previously. 18,19 Continuous variables were expressed as arithmetic mean SD if normally distributed or otherwise by median with 25% and 75% percentiles. Because explorative data analysis was performed, no correction of the type I error was made. Differences between groups are given as mean or median differences. The 95% CIs are given for mean or median differences. Comparisons between 2 subgroups were performed with the Mann-Whitney U test (2-sided). Bivariate correlations were analyzed by Spearman s as indicated. Continuous variables were split into tertiles for univariate and multivariate analysis. Categorized biochemical characteristics (body mass index, systolic blood pressure, CRP, HDL cholesterol, and 8-iso-PGF 2 ) and risk factors of CHD (diabetes mellitus, hypercholesterolemia, hypertension, and cigarette smoking) were included into the unconditional logistic regression models. Biochemical characteristics were included stepwise in one multivariate model and risk factors of CHD, including 8-iso-PGF 2, in a second multivariate model. Estimates of risk (odds ratios) and 95% CI were calculated on the basis of coefficients from the logistic regression models. For statistical analyses, SPSS version 11.0 was used. Results We enrolled 93 CHD patients and 93 controls, frequencymatched by sex and age. Characteristics of patients and controls are given in Table 1. Total cholesterol, LDL cholesterol, HDL cholesterol, and triglyceride levels were lower in patients than in controls. Systolic blood pressure and body mass index were higher in the CHD group. Oxidative stress and inflammation were evaluated by oxidized LDL, isoprostanes, and high-sensitive CRP, respectively. CRP was more abundant in patients. Oxidized LDL was not different in patients and controls. The prevalence of cardiovascular risk factors for both groups is given in Table 2. As expected, patients were more likely to have diabetes mellitus, hypercholesterolemia, or hypertension. Patients were also more often smokers. Likewise, lipid-lowering agents (64% versus 6%, patients and controls, respectively), -blockers (61% versus 6%), ACE inhibitors (47% versus 3%), calcium antagonists (17% versus 6%), nitrates (62% versus 1%), and aspirin (100% versus 4%) were used more frequently in patients. Urinary excretion of 8-iso-PGF 2 was 139 (93 231) pmol/mmol creatinine in patients and 77 (61 101) pmol/ mmol creatinine in controls (P 0.001, Figure 1). Excretion of 8-iso-PGF 2 metabolite was 193 ( ) pmol/mmol creatinine in patients and 120 (91 151) pmol/mmol creatinine in controls (P 0.001). Individual urinary excretion of the
3 Schwedhelm et al 8-iso-Prostaglandin F 2 and CHD 845 TABLE 1. Characteristics of Patients All (n 186) Controls Cases Difference Between Groups Difference* 95% CI* P Age, y 63.5 (9.1) 63.5 (7.9) 63.4 (10.3) Sex, M/F 160/26 80/13 80/13 Body mass index, kg/m (3.6) 25.7 (3.4) 27.2 (3.6) to Blood pressure, mm Hg Systolic 141 (20) 136 (16) 145 (24) to Diastolic 84 (11) 82 (10) 85 (12) to Plasma lipids, mmol/l Total cholesterol 5.1 ( ) 5.4 ( ) 4.7 ( ) to HDL cholesterol 0.9 ( ) 1.0 ( ) 0.9 ( ) to LDL cholesterol 3.2 ( ) 3.6 ( ) 2.7 ( ) to Triglycerides 1.2 ( ) 1.4 ( ) 1.0 ( ) to CRP high-sensitive, mg/l 1.6 ( ) 1.1 ( ) 3.7 ( ) to Creatinine clearance, ml/min 80 (25) 78 (22) 83 (28) to Oxidized LDL, U/L 31 (23 40) 31 (25 40) 30 (22 41) to Data are mean (SD) except for plasma lipids, CRP high-sensitive, and oxidized LDL, which are median (1st and 3rd quartiles). *Mean or median. Mann-Whitney U test (two-sided). Controls were matched for these criteria. To convert values for cholesterol to mg/dl, divide by ; to convert values for triglycerides to mg/dl, divide by metabolite was highly dependent on 8-iso-PGF 2 excretion ( 0.664, P 0.001). Neither 8-iso-PGF 2 nor its metabolite correlated with blood pressure, total cholesterol, LDL cholesterol, or HDL cholesterol. Treatment with lipid-lowering agents, -blockers, ACE inhibitors, calcium antagonists, and nitrates was not associated with reduced urinary excretion of 8-iso-PGF 2 or its metabolite in patients. There was no correlation between the 2 isoprostanes and oxidized LDL. However, a correlation was found between 8-iso-PGF 2, 2,3-dinor-5,6-dihydro-8-iso-PGF 2, and CRP ( 0.225, P 0.01, and 0.321, P 0.001, respectively). Urinary excretion of 8-iso-PGF 2 correlated with the number of cardiovascular risk factors in the 2 groups (P for trend, Figure 2). On univariate analysis, tertiles of body mass index, systolic blood pressure, CRP, and 8-iso-PGF 2 were concentrationdependent risk markers of CHD (Table 2). The odds ratio for HDL cholesterol was decreased for plasma levels 0.9 mmol/l. Diabetes mellitus, hypercholesterolemia, hypertension, cigarette smoking, and obesity (body mass index 30 kg/m 2 ) predicted CHD in univariate analysis as well. On multivariate analysis, the categorized characteristics of patients, including body mass index ( 30 kg/m 2 ), systolic blood pressure, CRP, HDL cholesterol, and 8-iso-PGF 2, were tested as independent markers of CHD (Table 3). Only urinary excretion of 8-iso-PGF 2 remained a strong risk marker in the 2 higher tertiles. The odds ratios were increased by 4.61 for 8-iso-PGF 2 levels 80 pmol/mmol creatinine and by 30.8 for 8-iso-PGF 2 levels 130 pmol/mmol creatinine. For CRP, an increased risk was found only for the highest tertile, ie, by 7.20 for CRP 3.0 mg/l. In a second model of multivariate analysis, tertiles of 8-iso-PGF 2 were included together with risk factors of CHD (Table 4). Included risk factors were diabetes mellitus, hypercholesterolemia, hypertension, and cigarette smoking. With the exception of cigarette smoking, all other risk factors remained strong and independent predictors of CHD. 8-iso- PGF 2 was found to be a strong concentration-dependent risk marker in this logistic regression model also. Discussion Cardiovascular risk is believed to be at least in part related to increased systemic oxidative stress. Established risk factors of CHD have been associated with elevated levels of markers of systemic oxidative stress such as isoprostanes However, such evidence is restricted to single risk factors. The principal result of our study is that systemic oxidative stress, evaluated as creatinine-indexed urinary isoprostanes, is related to the number of cardiovascular risk factors as well as to the prevalence of CHD. Other categorized patients characteristics, such as body mass index, systolic blood pressure, HDL cholesterol, and CRP, included in univariate analysis also predicted the prevalence of CHD (Table 2). However, in multivariate analysis, only isoprostane and CRP remained independent risk markers of CHD. Cigarette smoking, hypertension, hypercholesterolemia, diabetes mellitus, and obesity are well-known risk factors of CHD. 13 With the exception of obesity, they also predicted the prevalence of CHD in our study. Obesity missed the significance level probably because of its comparatively low prevalence and was therefore not included into the multivariate analysis. Included risk factors, ie, diabetes mellitus, arterial hypertension, and hypercholesterolemia remained strong predictors of CHD in multivariate regression analysis. 8-iso-PGF 2 divided into tertiles was found to be a strong predictor of CHD in this model as well. The odds ratio was significantly elevated for levels of
4 846 Circulation February 24, 2004 TABLE 2. Risk Factors for CHD in Univariate Analysis* All (n 186) 8-iso-PGF 2 80 pmol/mmol creatinine. The close relationship previously observed between cigarette smoking and increased lipid peroxidation may explain why cigarette smoking was not found to be an independent risk marker in Controls Cases Odds Ratios (95% CI) P Body mass index, kg/m (34) 41 (44) 23 (25) (49) 40 (43) 51 (55) 2.27 ( ) (17) 12 (13) 19 (20) 2 82 ( ) 0.02 Systolic blood pressure, mm Hg (41) 52 (56) 24 (26) (37) 29 (31) 40 (43) 2.99 ( ) (22) 12 (13) 29 (31) 5.24 ( ) CRP high-sensitive, mg/l (29) 34 (45) 9 (13) (34) 29 (38) 21 (29) 2.74 ( ) (37) 13 (17) 42 (58) 12.2 ( ) Unknown HDL cholesterol, mmol/l (40) 22 (27) 40 (55) (60) 59 (73) 33 (45) 0.31 ( ) Unknown iso-PGF 2a, pmol/mmol (33) 53 (57) 9 (10) (33) 29 (31) 33 (35) 6.70 ( ) (33) 11 (12) 51 (55) 27.3 ( ) Diabetes mellitus 28 (15) 3 (3) 25 (27) 11.0 ( ) Hypercholesterolemia 93 (50) 24 (26) 69 (74) 8.27 ( ) Hypertension 139 (75) 50 (54) 89 (96) 19.1 ( ) Cigarette smoking Never 70 (39) 45 (51) 25 (27) 1.00 Former 93 (51) 42 (47) 51 (55) 2.19 ( ) 0.02 Current 19 (10) 2 (2) 17 (18) 15.2 ( ) Unknown 4 4 Data are counts (% of known). *In 93 patients and 93 controls frequency-matched by age and sex. Reference. LDL cholesterol 4.1 mmol/l, total cholesterol 6.2 mmol/l, or statin. Blood pressure 140/90 mm Hg or antihypertensive drug. multivariate analysis. 12 However, our results confirm previous studies showing increased isoprostane formation in diabetes mellitus, renal hypertension, hypercholesterolemia, and cigarette smoking. 8 10,12 Furthermore, they are in line with Figure 1. Creatinine-indexed urinary excretion of 8-iso-PGF 2 and its urinary metabolite 2,3-dinor-5,6-dihydro-8-iso- PGF 2 in 93 patients with CHD and 93 age- and sex-matched controls. Median, interquartile range, outliers, and extremes of urinary excretion are given; *P
5 Schwedhelm et al 8-iso-Prostaglandin F 2 and CHD 847 TABLE 4. Odds Ratios From a Multivariate Logistic Regression Model Including Risk Factors of CHD* Figure 2. Creatinine-indexed urinary excretion of 8-iso-PGF 2 and risk factors of CHD. Risk factors for CHD are obesity, diabetes mellitus, hypercholesterolemia, hypertension, and smoking. Median, interquartile range, outliers, and extremes of urinary excretion are given; P for trend. recent findings from the Framingham study showing an association between urinary excretion of 8-iso-PGF 2 and history of cardiovascular disease, smoking, and body mass index. 18 Moreover, our data show for the first time that systemic oxidative stress is an additive risk marker of CHD in addition to traditional risk factors (Table 4). In line with this result, urinary excretion of 8-iso-PGF 2 continuously increased with the number of traditional CHD risk factors (Figure 2). To confirm the validity of our data, we correlated 8-iso- PGF 2 with its major urinary metabolite, 2,3-dinor-5,6- dihydro-8-iso-pgf 2. We found a very good correlation (Spearman s 0.66) analyzing both parameters with GCtandem MS. Both were highly different between case subjects TABLE 3. Multivariate Model* Predicting CHD Odds Ratio (95% CI) P Body mass index, kg/m ( ) 0.61 Systolic blood pressure, mm Hg ( ) ( ) 0.13 CRP high-sensitive, mg/l ( ) ( ) 0.01 HDL cholesterol, mmol/l ( ) iso-PGF 2a, pmol/mmol ( ) ( ) *A stepwise regression model including categorized biochemical characteristics in 93 patients and 93 controls frequency-matched by age and sex. Adjusted for variables. Reference. Odds Ratio (95% CI) P Diabetes mellitus 7.8 ( ) 0.01 Hypercholesterolemia 12.1 ( ) Hypertension 20.6 ( ) Cigarette smoking Never 1.00 Former 2.5 ( ) 0.06 Current 2.8 ( ) iso-PGF 2a, pmol/mmol ( ) ( ) *A stepwise model including risk factors for CHD in 93 patients and 93 controls frequency-matched by age and sex. Adjusted for variables. Reference. (cases) and controls (P 0.001). Further evidence for the suitability of 8-iso-PGF 2 as a novel risk marker comes from analysis of possible confounders. Not surprisingly, in our cohort of cases, we found decreased levels of total cholesterol, LDL cholesterol, and triglycerides, reflecting the widespread use of lipid-lowering therapy in CHD patients (64%). Urinary excretion of 8-iso-PGF 2 and its metabolite were not confounded by either lipid-lowering therapy or by total cholesterol, LDL cholesterol, or triglyceride levels. This finding is of particular interest, because it has been demonstrated that intervention with statins in mildly hypercholesterolemic patients reduced oxidant burden, ie, 8-iso-PGF 2 and 3-nitrotyrosine formation. 20,21 However, our trial was designed as a case-control study and therefore was not intended to detect such effects. Recently, a difference in urinary 8-iso-PGF 2 in CHD patients with 1-vessel and multivessel disease was found. 22 Unfortunately, we were not able to confirm this observation in our study (data not shown). Interestingly, a correlation between 8-iso-PGF 2, its metabolite, and CRP existed ( 0.23 and 0.32, respectively; P 0.01). This observation may result in part from the involvement of inflammatory and oxidative processes in atherosclerosis. 1,23,24 Moderately elevated CRP is associated with a high risk of coronary events, possibly because of inflammation of the vascular bed. 25 Although inflammation works hand in hand with oxidative modifications, oxidative stress may occur independently of inflammation. In support of this, we found 8-iso-PGF 2 and high-sensitive CRP to be independent predictors of CHD (Table 3). Thus, the evaluation of both 8-iso-PGF 2 and CRP should be superior to the measurement of either parameter alone. Another parameter of lipid peroxidation, oxidized LDL, failed to show a difference in our case-control design. There is substantial evidence that oxidized LDL is present in vivo within atherosclerotic blood vessels. 26,27 Probably, circulating oxidized LDL derives, at least in part, from rupture of atherosclerotic plaques. Thus,
6 848 Circulation February 24, 2004 elevated levels of oxidized LDL showed a positive correlation with the severity of acute coronary events. 28 Because acute coronary syndrome and related conditions were excluded in our study, this could explain the similar levels of oxidized LDL in both groups. Interestingly, Cipollone et al 29 previously reported highly elevated urinary 8-iso-PGF 2 measured in patients with unstable angina, supporting the important role of oxidative stress in a worse scenario than investigated in our study. In conclusion, our findings introduce 8-iso-PGF 2 as a new risk marker in the field of cardiovascular disease. 8-iso-PGF 2 was identified as an independent and cumulative risk marker of CHD together with diabetes mellitus, arterial hypertension, hypercholesterolemia, and elevated CRP. The case-control design used in our study does not allow us to show the value of 8-iso-PGF 2 for predicting future coronary events. Therefore, we initiated a cohort study to evaluate 8-iso-PGF 2 as a risk factor for coronary events. Acknowledgments We thank A. Steenpaß, T. Suchy, and B. Schubert for excellent technical assistance and the patients and healthy volunteers who participated in this study. References 1. Harrison D, Griendling KK, Landmesser U, et al. Role of oxidative stress in atherosclerosis. Am J Cardiol. 2003;91:7A 11A. 2. Dhalla NS, Temsah RM, Netticadan T. Role of oxidative stress in cardiovascular disease. J Hypertens. 2000;18: Cracowski JL, Durand T, Bessard G. Isoprostanes as a biomarker of lipid peroxidation in humans: physiology, pharmacology and clinical implications. Trends Pharmacol Sci. 2002;23: Thérond P, Bonnefont-Rousselot D, Davit-Spraul A, et al. Biomarkers of oxidative stress: an analytical approach. Curr Opin Clin Nutr Metab Care. 2000;3: Morrow JD, Hill KE, Burk RF, et al. A series of prostaglandin F 2 -like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci U S A. 1990;87: Morrow JD. The isoprostanes: their quantification as an index of oxidant stress status in vivo. Drug Metab Rev. 2000;32: Lawson JA, Rokach J, FitzGerald GA. Isoprostanes: formation, analysis and use as indices of lipid peroxidation. J Biol Chem. 1999;274: Davi G, Ciabattoni G, Consoli A, et al. In vivo formation of 8-iso-prostaglandin F 2 and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation. 1999;99: Minuz P, Patrignani P, Gaino S, et al. Increased oxidative stress and platelet activation in patients with hypertension and renovascular disease. Circulation. 2002;106: Davi G, Alessandrini P, Mezzetti A, et al. In vivo formation of 8-isoprostaglandin F 2 is increased in hypercholesterolemia. Arterioscler Thromb Vasc Biol. 1997;17: Davi G, Guagnano MT, Ciabattoni G, et al. Platelet activation in obese women: role of inflammation and oxidant stress. JAMA. 2002;288: Morrow JD, Frei B, Longmire AW, et al. Increase in circulating products of lipid peroxidation (F 2 -isoprostanes) in smokers: smoking as a cause of oxidative damage. N Engl J Med. 1995;332: Grundy SM, Pasternak R, Greenland P, et al. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation. 1999;100: Helmersson J, Basu S. F 2 -isoprostane excretion rate and diurnal variation in human urine. Prostaglandins Leukot Essent Fatty Acids. 1999;61: Schwedhelm E, Tsikas D, Durand T, et al. Tandem mass spectrometric quantification of 8-iso-prostaglandin F 2 and its metabolite 2,3-dinor-5,6- dihydro-8-iso-prostaglandin F 2 in human urine. J Chromatogr B. 2000; 744: Tsikas D, Schwedhelm E, Fauler J, et al. Specific and rapid quantification of 8-iso-prostaglandin F 2 in urine of healthy humans and patients with Zellweger syndrome by gas chromatography-tandem mass spectrometry. J Chromatogr B. 1998;716: Ledue TB, Weiner DL, Sipe JD, et al. Analytical evaluation of a particleenhanced immunonephelometric assay for C-reactive protein, serum amyloid A and mannose-binding protein in human serum. Ann Clin Biochem. 1998;35: Keaney JF Jr, Larson MG, Vasan RS, et al. Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham study. Arterioscler Thromb Vasc Biol. 2003;23: Koenig W, Sund M, Frohlich M, et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to Circulation. 1999;99: Shishehbor MH, Aviles RJ, Brennan ML, et al. Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy. JAMA. 2003;289: De Caterina R, Cipollone F, Filardo FP, et al. Low-density lipoprotein level reduction by the 3-hydroxy-3-methylglutaryl coenzyme-a inhibitor simvastatin is accompanied by a related reduction of F 2 -isoprostane formation in hypercholesterolemic subjects: no further effect of vitamin E. Circulation. 2002;106: Vassalle C, Botto N, Andreassi MG, et al. Evidence for enhanced 8-isoprostane plasma levels, as index of oxidative stress in vivo, in patients with coronary artery disease. Coron Artery Dis. 2003;14: Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999; 340: Diaz MN, Frei B, Vita JA, et al. Mechanism of disease: antioxidants and atherosclerotic heart disease. N Engl J Med. 1997;337: Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347: Kuhn H, Heydeck D, Hugou I, et al. In vivo action of 15-lipoxygenase in early stages of human atherogenesis. J Clin Invest. 1997;99: Watson AD, Leitinger N, Navab M, et al. Structural identification by mass spectrometry of oxidized phospholipids in minimally oxidized low density lipoprotein that induce monocyte/endothelial interactions and evidence for their presence in vivo. J Biol Chem. 1997;272: Ehara S, Ueda M, Naruko T, et al. Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation. 2001;103: Cipollone F, Ciabattoni G, Patrignani P, et al. Oxidant stress and aspirininsensitive thromboxane biosynthesis in severe unstable angina. Circulation. 2000;102:
The Framingham Coronary Heart Disease Risk Score
Plasma Concentration of C-Reactive Protein and the Calculated Framingham Coronary Heart Disease Risk Score Michelle A. Albert, MD, MPH; Robert J. Glynn, PhD; Paul M Ridker, MD, MPH Background Although
More informationAssociation of Type 2 Diabetes With Cyclooxygenase- Mediated Inflammation and Oxidative Stress in an Elderly Population
Association of Type 2 Diabetes With Cyclooxygenase- Mediated Inflammation and Oxidative Stress in an Elderly Population Johanna Helmersson, MD; Bengt Vessby, MD, PhD; Anders Larsson, MD, PhD; Samar Basu,
More informationORIGINAL INVESTIGATION. C-Reactive Protein Concentration and Incident Hypertension in Young Adults
ORIGINAL INVESTIGATION C-Reactive Protein Concentration and Incident Hypertension in Young Adults The CARDIA Study Susan G. Lakoski, MD, MS; David M. Herrington, MD, MHS; David M. Siscovick, MD, MPH; Stephen
More informationJUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study
Panel Discussion: Literature that Should Have an Impact on our Practice: The Study Kaiser COAST 11 th Annual Conference Maui, August 2009 Robert Blumberg, MD, FACC Ralph Brindis, MD, MPH, FACC Primary
More informationCurrent Cholesterol Guidelines and Treatment of Residual Risk COPYRIGHT. J. Peter Oettgen, MD
Current Cholesterol Guidelines and Treatment of Residual Risk J. Peter Oettgen, MD Associate Professor of Medicine Harvard Medical School Director, Preventive Cardiology Beth Israel Deaconess Medical Center
More informationJohn J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam
Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention
More informationA: Epidemiology update. Evidence that LDL-C and CRP identify different high-risk groups
A: Epidemiology update Evidence that LDL-C and CRP identify different high-risk groups Women (n = 27,939; mean age 54.7 years) who were free of symptomatic cardiovascular (CV) disease at baseline were
More informationEmmanouil S. Brilakis 1{, Joseph P. McConnell 2, Ryan J. Lennon 3, Ahmad A. Elesber 1, Jeffrey G. Meyer 2, and Peter B. Berger 4 * Introduction
European Heart Journal (2005) 26, 137 144 doi:10.1093/eurheartj/ehi010 Clinical research Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic
More informationCorrelation of novel cardiac marker
Correlation of novel cardiac marker and mortality in EGAT population. Soluble ST2 hscrp Poh Chanyavanich, MD SukitYamwong, MD Piyamitr Sritara, MD Ramathibodi hospital Background hscrp - the most widely
More informationThe Framingham Risk Score (FRS) is widely recommended
C-Reactive Protein Modulates Risk Prediction Based on the Framingham Score Implications for Future Risk Assessment: Results From a Large Cohort Study in Southern Germany Wolfgang Koenig, MD; Hannelore
More information10/17/16. Assessing cardiovascular risk through use of inflammation testing
Assessing cardiovascular risk through use of inflammation testing Anthony L. Lyssy, DO Medical Director and Managing Partner Diamond Physicians Dallas, TX Response to Injury Hypothesis Injury Response
More informationUpdate on Lipid Management in Cardiovascular Disease: How to Understand and Implement the New ACC/AHA Guidelines
Update on Lipid Management in Cardiovascular Disease: How to Understand and Implement the New ACC/AHA Guidelines Paul Mahoney, MD Sentara Cardiology Specialists Lipid Management in Cardiovascular Disease
More information(n=6279). Continuous variables are reported as mean with 95% confidence interval and T1 T2 T3. Number of subjects
Table 1. Distribution of baseline characteristics across tertiles of OPG adjusted for age and sex (n=6279). Continuous variables are reported as mean with 95% confidence interval and categorical values
More informationLow fractional diastolic pressure in the ascending aorta increased the risk of coronary heart disease
(2002) 16, 837 841 & 2002 Nature Publishing Group All rights reserved 0950-9240/02 $25.00 www.nature.com/jhh ORIGINAL ARTICLE Low fractional diastolic pressure in the ascending aorta increased the risk
More informationAutonomic nervous system, inflammation and preclinical carotid atherosclerosis in depressed subjects with coronary risk factors
Autonomic nervous system, inflammation and preclinical carotid atherosclerosis in depressed subjects with coronary risk factors Carmine Pizzi 1 ; Lamberto Manzoli 2, Stefano Mancini 3 ; Gigliola Bedetti
More informationJournal of the American College of Cardiology Vol. 36, No. 1, by the American College of Cardiology ISSN /00/$20.
Journal of the American College of Cardiology Vol. 36, No. 1, 2000 2000 by the American College of Cardiology ISSN 0735-1097/00/$20.00 Published by Elsevier Science Inc. PII S0735-1097(00)00680-X Lack
More informationThe JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009
The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain
More informationVal-MARC: Valsartan-Managing Blood Pressure Aggressively and Evaluating Reductions in hs-crp
Página 1 de 5 Return to Medscape coverage of: American Society of Hypertension 21st Annual Scientific Meeting and Exposition Val-MARC: Valsartan-Managing Blood Pressure Aggressively and Evaluating Reductions
More informationSTABILITY Stabilization of Atherosclerotic plaque By Initiation of darapladib TherapY. Harvey D White on behalf of The STABILITY Investigators
STABILITY Stabilization of Atherosclerotic plaque By Initiation of darapladib TherapY Harvey D White on behalf of The STABILITY Investigators Lipoprotein- associated Phospholipase A 2 (Lp-PLA 2 ) activity:
More information9/29/2015. Primary Prevention of Heart Disease: Objectives. Objectives. What works? What doesn t?
Primary Prevention of Heart Disease: What works? What doesn t? Samia Mora, MD, MHS Associate Professor, Harvard Medical School Associate Physician, Brigham and Women s Hospital October 2, 2015 Financial
More informationPrevalence of High C-Reactive Protein in Persons with Serum Lipid Concentrations within Recommended Values
Papers in Press. First published June 17, 2004 as doi:10.1373/clinchem.2004.036004 Clinical Chemistry 50:9 000 000 (2004) Lipids, Lipoproteins, and Cardiovascular Risk Factors Prevalence of High C-Reactive
More informationEffects of Statins on Endothelial Function in Patients with Coronary Artery Disease
Effects of Statins on Endothelial Function in Patients with Coronary Artery Disease Iana I. Simova, MD; Stefan V. Denchev, PhD; Simeon I. Dimitrov, PhD Clinic of Cardiology, University Hospital Alexandrovska,
More informationHIGH LDL CHOLESTEROL IS NOT AN INDEPENDENT RISK FACTOR FOR HEART ATTACKS AND STROKES
HIGH LDL CHOLESTEROL IS NOT AN INDEPENDENT RISK FACTOR FOR HEART ATTACKS AND STROKES A study published in the British Medical Journal shows that not only is high LDL cholesterol not a risk factor for all-caused
More informationSMARTool clinical and biohumoral results. Chiara Caselli IFC-CNR
SMARTool clinical and biohumoral results Chiara Caselli IFC-CNR SMARTool Flow chart EVINCI and ARTreat Populations SMARTool: WP1 and WP2 WP1 Objective: To collect retrospective EVINCI clinical and imaging
More informationInflammation plays a major role in atherosclerosis, 1 and
Soluble P-Selectin and the Risk of Future Cardiovascular Events Paul M. Ridker, MD; Julie E. Buring, ScD; Nader Rifai, PhD Background P-selectin, a cell-surface adhesion molecule involved in leukocyte
More informationHow would you manage Ms. Gold
How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56
More informationInflammation in Renal Disease
Inflammation in Renal Disease Donald G. Vidt, MD Inflammation is a component of the major modifiable risk factors in renal disease. Elevated high-sensitivity C-reactive protein (hs-crp) levels have been
More informationResearch Article Comparison of Different Anthropometric Measurements and Inflammatory Biomarkers
International Inflammation Volume 2012, Article ID 124693, 5 pages doi:10.1155/2012/124693 Research Article Comparison of Different Anthropometric Measurements and Inflammatory Biomarkers Yaron Arbel,
More informationThe inhibition of CETP: From simply raising HDL-c to promoting cholesterol efflux and lowering of atherogenic lipoproteins Prof Dr J Wouter Jukema
The inhibition of CETP: From simply raising HDL-c to promoting cholesterol efflux and lowering of atherogenic lipoproteins Prof Dr J Wouter Jukema Dept Cardiology, Leiden University Medical Center, Leiden,
More informationLOOKING FOR LIPID PEROXIDATION IN VITRO AND IN VIVO: IS SEEING BELIEVING? Vanderbilt University School of Medicine Jason D.
LOOKING FOR LIPID PEROXIDATION IN VITRO AND IN VIVO: IS SEEING BELIEVING? Vanderbilt University School of Medicine Jason D. Morrow MD Which of the following assays of lipid peroxidation may be useful and
More informationCardiovascular Complications of Diabetes
VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary
More informationSupplementary Online Content
Supplementary Online Content Kavousi M, Leening MJG, Nanchen D, et al. Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines
More informationCentral pressures and prediction of cardiovascular events in erectile dysfunction patients
Central pressures and prediction of cardiovascular events in erectile dysfunction patients N. Ioakeimidis, K. Rokkas, A. Angelis, Z. Kratiras, M. Abdelrasoul, C. Georgakopoulos, D. Terentes-Printzios,
More informationHigh-sensitivity Troponin T Predicts Recurrent Cardiovascular Events in Patients with Stable Coronary Heart Disease: KAROLA Study 8 Year FU
ESC Congress 2011 Paris, France, August 27-31 KAROLA Session: Prevention: Are biomarkers worth their money? Abstract # 84698 High-sensitivity Troponin T Predicts Recurrent Cardiovascular Events in Patients
More informationSerum Creatinine and Blood Urea Nitrogen Levels in Patients with Coronary Artery Disease
Serum Creatinine and Blood Urea Nitrogen Levels in Patients with Coronary Artery Disease MAK Akanda 1, KN Choudhury 2, MZ Ali 1, MK Kabir 3, LN Begum 4, LA Sayami 1 1 National Institute of Cardiovascular
More informationModerate alcohol consumption is associated with decreased
Alcohol Consumption and Plasma Concentration of C-Reactive Protein Michelle A. Albert, MD, MPH; Robert J. Glynn, PhD; Paul M Ridker, MD, MPH Background Moderate alcohol intake has been associated with
More informationTargeting intracellular arginine / asymmetric dimethylarginine (ADMA).
Targeting intracellular arginine / asymmetric dimethylarginine (ADMA). From bench to practice: Novel anti-atherogenic strategies to improve endothelial function Rainer H. Böger, M.D. Institute of Clinical
More informationInflammation and and Heart Heart Disease in Women Inflammation and Heart Disease
Inflammation and Heart Disease in Women Inflammation and Heart Disease What is the link between een inflammation and atherosclerotic disease? What is the role of biomarkers in predicting cardiovascular
More informationjournal of medicine The new england Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein Abstract
The new england journal of medicine established in 1812 november 20, 2008 vol. 359 no. 21 to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein Paul M Ridker, M.D., Eleanor Danielson,
More informationSerum levels of galectin-1, galectin-3, and galectin-9 are associated with large artery atherosclerotic
Supplementary Information The title of the manuscript Serum levels of galectin-1, galectin-3, and galectin-9 are associated with large artery atherosclerotic stroke Xin-Wei He 1, Wei-Ling Li 1, Cai Li
More informationTracking a Killer Molecule
Tracking a Killer Molecule Mercodia Oxidized LDL ELISA www.mercodia.com Mercodia Oxidized LDL ELISA products Product Catalog No Kit size Oxidized LDL ELISA 10-1143-01 96 wells Oxidized LDL competitive
More informationEicosapentaenoic Acid and Docosahexaenoic Acid: Are They Different?
Eicosapentaenoic Acid and Docosahexaenoic Acid: Are They Different? Trevor A Mori, Ph.D., Professor, School of Medicine and Pharmacology, Royal Perth Hospital Unit, University of Western Australia, Perth,
More informationImpact of coronary atherosclerotic burden on clinical presentation and prognosis of patients with coronary artery disease
Impact of coronary atherosclerotic burden on clinical presentation and prognosis of patients with coronary artery disease Gjin Ndrepepa, Tomohisa Tada, Massimiliano Fusaro, Lamin King, Martin Hadamitzky,
More informationDiabetologia 9 Springer-Verlag 1991
Diabetologia (1991) 34:590-594 0012186X91001685 Diabetologia 9 Springer-Verlag 1991 Risk factors for macrovascular disease in mellitus: the London follow-up to the WHO Multinational Study of Vascular Disease
More informationThe New England Journal of Medicine C-REACTIVE PROTEIN AND OTHER MARKERS OF INFLAMMATION IN THE PREDICTION OF CARDIOVASCULAR DISEASE IN WOMEN
C-REACTIVE PROTEIN AND OTHER MARKERS OF INFLAMMATION IN THE PREDICTION OF CARDIOVASCULAR DISEASE IN WOMEN PAUL M. RIDKER, M.D., CHARLES H. HENNEKENS, M.D., JULIE E. BURING, SC.D., AND NADER RIFAI, PH.D.
More informationTerm-End Examination December, 2009 MCC-006 : CARDIOVASCULAR EPIDEMIOLOGY
MCC-006 POST GRADUATE DIPLOMA IN CLINICAL CARDIOLOGY (PGDCC) 00269 Term-End Examination December, 2009 MCC-006 : CARDIOVASCULAR EPIDEMIOLOGY Time : 2 hours Maximum Marks : 60 Note : There will be multiple
More informationAssessment of vitamin D levels in patients with acute coronary syndrome
ORIGINAL ARTICLE East J Med 21(4): 178-182, 2016 Assessment of vitamin D levels in patients with acute coronary syndrome Hakki Simsek and Naci Babat * Yuzuncu Yil University, Faculty of Medicine, Cardiology
More informationImaging Biomarkers: utilisation for the purposes of registration. EMEA-EFPIA Workshop on Biomarkers 15 December 2006
Imaging Biomarkers: utilisation for the purposes of registration EMEA-EFPIA Workshop on Biomarkers 15 December 2006 Vascular Imaging Technologies Carotid Ultrasound-IMT IVUS-PAV QCA-% stenosis 2 ICH E
More informationTable S1. Characteristics associated with frequency of nut consumption (full entire sample; Nn=4,416).
Table S1. Characteristics associated with frequency of nut (full entire sample; Nn=4,416). Daily nut Nn= 212 Weekly nut Nn= 487 Monthly nut Nn= 1,276 Infrequent or never nut Nn= 2,441 Sex; n (%) men 52
More informationDivision of Cardiovascular Medicine, Jichi Medical University Saitama Medical Center, Japan
Association between continuously elevated C-reactive protein and restenosis after percutaneous coronary intervention using drug-eluting stent in angina patients Division of Cardiovascular Medicine, Jichi
More information2013 Cholesterol Guidelines. Anna Broz MSN, RN, CNP, AACC Adult Certified Nurse Practitioner North Ohio Heart, Inc.
2013 Cholesterol Guidelines Anna Broz MSN, RN, CNP, AACC Adult Certified Nurse Practitioner North Ohio Heart, Inc. Disclosures Speaker Gilead Sciences NHLBI Charge to the Expert Panel Evaluate higher quality
More informationSpotty Calcification as a Marker of Accelerated Progression of Coronary Atherosclerosis : Insights from Serial Intravascular Ultrasound
Spotty Calcification as a Marker of Accelerated Progression of Coronary Atherosclerosis : Insights from Serial Intravascular Ultrasound Department of Cardiovascular Medicine Heart and Vascular Institute
More informationCLINICAL OUTCOME Vs SURROGATE MARKER
CLINICAL OUTCOME Vs SURROGATE MARKER Statin Real Experience Dr. Mostafa Sherif Senior Medical Manager Pfizer Egypt & Sudan Objective Difference between Clinical outcome and surrogate marker Proper Clinical
More informationLDL cholesterol (p = 0.40). However, higher levels of HDL cholesterol (> or =1.5 mmol/l [60 mg/dl]) were associated with less progression of CAC
Am J Cardiol (2004);94:729-32 Relation of degree of physical activity to coronary artery calcium score in asymptomatic individuals with multiple metabolic risk factors M. Y. Desai, et al. Ciccarone Preventive
More informationAppendix This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors.
Appendix This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors. Appendix to: Banks E, Crouch SR, Korda RJ, et al. Absolute risk of cardiovascular
More informationPreventing Myocardial Infarction in the Young Adult in the First Place: How Do the National Cholesterol Education Panel III Guidelines Perform?
Journal of the American College of Cardiology Vol. 41, No. 9, 2003 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Inc. doi:10.1016/s0735-1097(03)00187-6
More information1. Which one of the following patients does not need to be screened for hyperlipidemia:
Questions: 1. Which one of the following patients does not need to be screened for hyperlipidemia: a) Diabetes mellitus b) Hypertension c) Family history of premature coronary disease (first degree relatives:
More informationLipoprotein Particle Profile
Lipoprotein Particle Profile 50% of people at risk for HEART DISEASE are not identified by routine testing. Why is LPP Testing The Most Comprehensive Risk Assessment? u Provides much more accurate cardiovascular
More information300 Biomed Environ Sci, 2018; 31(4):
300 Biomed Environ Sci, 2018; 31(4): 300-305 Letter to the Editor Combined Influence of Insulin Resistance and Inflammatory Biomarkers on Type 2 Diabetes: A Population-based Prospective Cohort Study of
More informationPrevalence of Low Low-Density Lipoprotein Cholesterol With Elevated High Sensitivity C-Reactive Protein in the U.S.
Journal of the American College of Cardiology Vol. 53, No. 11, 2009 2009 by the American College of Cardiology Foundation ISSN 0735-1097/09/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2008.12.010
More informationEpidemiologic and clinical comparison of renal artery stenosis in black patients and white patients
ORIGINAL ARTICLES Epidemiologic and clinical comparison of renal artery stenosis in black patients and white patients Andrew C. Novick, MD, Safwat Zald, MD, David Goldfarb, MD, and Ernest E. Hodge, MD,
More informationEnvironmental. Vascular / Tissue. Metabolics
Global Risk Reduction--WINS Picking Mom and Dad-2016 Environmental Vascular / Tissue Metabolics Stop smoking-1b Physical activity-1b Weight control-1b Chelation therapy-3c Influenza vaccination-1b Blood
More informationC-Reactive Protein Levels and Outcomes after Statin Therapy
The new england journal of medicine original article C-Reactive Protein Levels and Outcomes after Statin Therapy Paul M Ridker, M.D., Christopher P. Cannon, M.D., David Morrow, M.D., Nader Rifai, Ph.D.,
More informationDespite the availability of effective preventive therapies,
Combined Use of Computed Tomography Coronary Calcium Scores and C-Reactive Protein Levels in Predicting Cardiovascular Events in Nondiabetic Individuals Robert Park, MD; Robert Detrano, MD, PhD; Min Xiang,
More informationAndrejs Kalvelis 1, MD, PhD, Inga Stukena 2, MD, Guntis Bahs 3 MD, PhD & Aivars Lejnieks 4, MD, PhD ABSTRACT INTRODUCTION. Riga Stradins University
CARDIOVASCULAR RISK FACTORS ORIGINAL ARTICLE Do We Correctly Assess the Risk of Cardiovascular Disease? Characteristics of Risk Factors for Cardiovascular Disease Depending on the Sex and Age of Patients
More informationStatin pretreatment and presentation patterns in patients with acute coronary syndromes
Brief Report Page 1 of 5 Statin pretreatment and presentation patterns in patients with acute coronary syndromes Marcelo Trivi, Ruth Henquin, Juan Costabel, Diego Conde Cardiovascular Institute of Buenos
More informationΛΟΙΜΩΞΗ HIV. Ιγνάτιος Οικονομίδης,MD,FESC Β Πανεπιστημιακή Καρδιολογική
ΛΟΙΜΩΞΗ HIV Ιγνάτιος Οικονομίδης,MD,FESC Β Πανεπιστημιακή Καρδιολογική Κλινική, Νοσοκομείο «Αττικόν» Infection Acute Myocardial Infarction p er 100,000 HIV/AIDS discharg es 800 700 600 500 400 300 200
More informationDyslipidemia in the light of Current Guidelines - Do we change our Practice?
Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dato Dr. David Chew Soon Ping Senior Consultant Cardiologist Institut Jantung Negara Atherosclerotic Cardiovascular Disease
More informationFatality of Future Coronary Events Is Related to Inflammation-Sensitive Plasma Proteins
Fatality of Future Coronary Events Is Related to Inflammation-Sensitive Plasma Proteins A Population-Based Prospective Cohort Study Gunnar Engström, MD; Bo Hedblad, MD; Lars Stavenow, MD; Patrik Tydén,
More informationBiases in clinical research. Seungho Ryu, MD, PhD Kanguk Samsung Hospital, Sungkyunkwan University
Biases in clinical research Seungho Ryu, MD, PhD Kanguk Samsung Hospital, Sungkyunkwan University Learning objectives Describe the threats to causal inferences in clinical studies Understand the role of
More informationOptimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden
Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden Cardiovascular Disease Prevention (CVD) Three Strategies for CVD
More informationSetting The setting was the Walter Reed Army Medical Center. The economic study was carried out in the USA.
Coronary calcium independently predicts incident premature coronary heart disease over measured cardiovascular risk factors: mean three-year outcomes in the Prospective Army Coronary Calcium (PACC) project
More information2.0 Synopsis. Choline fenofibrate capsules (ABT-335) M Clinical Study Report R&D/06/772. (For National Authority Use Only) Name of Study Drug:
2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: Volume: Choline Fenofibrate (335) Name of Active Ingredient:
More informationVascular disease. Structural evaluation of vascular disease. Goo-Yeong Cho, MD, PhD Seoul National University Bundang Hospital
Vascular disease. Structural evaluation of vascular disease Goo-Yeong Cho, MD, PhD Seoul National University Bundang Hospital resistance vessels : arteries
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 6 October 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 6 October 2010 CRESTOR 5 mg, film-coated tablet B/30 (CIP code: 369 853-8) B/90 (CIP code: 391 690-0) CRESTOR 10 mg,
More informationMandana Nikpour 1,2, Murray B Urowitz 1*, Dominique Ibanez 1, Paula J Harvey 3 and Dafna D Gladman 1. Abstract
RESEARCH ARTICLE Open Access Importance of cumulative exposure to elevated cholesterol and blood pressure in development of atherosclerotic coronary artery disease in systemic lupus erythematosus: a prospective
More informationIschemic heart disease is the leading cause of
The impact of C-Reactive Protein: A Look at the Most Recent Studies and Trials By Davinder S. Jassal, MD, FRCPC; and Blair O Neill, MD, FRCPC, FACC Ischemic heart disease is the world s leading killer,
More informationC-Reactive Protein and Your Heart
C-Reactive Protein and Your Heart By: James L. Holly, MD Inflammation is the process by which the body responds to injury. Laboratory evidence and findings at autopsy studies suggest that the inflammatory
More informationegfr > 50 (n = 13,916)
Saxagliptin and Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Moderate or Severe Renal Impairment: Observations from the SAVOR-TIMI 53 Trial Supplementary Table 1. Characteristics according
More informationIntercommunale de Santé Publique du Pays de Charleroi, Charleroi, Belgium 2
Lipid Abnormalities Remain High among Treated Hypertensive Patients with Stable CHD: Results of the Dyslipidemia International Study (DYSIS) II Belgium Michel Guillaume 1, Eric Weber 2, Johan De Sutter
More informationAndrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION
2 Hyperlipidemia Andrew Cohen, MD and Neil S. Skolnik, MD CONTENTS INTRODUCTION RISK CATEGORIES AND TARGET LDL-CHOLESTEROL TREATMENT OF LDL-CHOLESTEROL SPECIAL CONSIDERATIONS OLDER AND YOUNGER ADULTS ADDITIONAL
More informationWeintraub, W et al NEJM March Khot, UN et al, JAMA 2003
Global risk hscrp Should not be included in a Global Cardiovascular Risk Assessment. Jodi Tinkel, MD Assistant Professor Director of Cardiac Rehabilitation Associate Program Director, Cardiovascular Medicine
More informationEzetimibe and SimvastatiN in Hypercholesterolemia EnhANces AtherosClerosis REgression (ENHANCE)
Ezetimibe and SimvastatiN in Hypercholesterolemia EnhANces AtherosClerosis REgression (ENHANCE) Thomas Dayspring, MD, FACP Clinical Assistant Professor of Medicine University of Medicine and Dentistry
More informationCase Study: Chris Arden. Peripheral Arterial Disease
Case Study: Chris Arden Peripheral Arterial Disease Patient Presentation Diane is a 65-year-old retired school teacher She complains of left calf pain when walking 50 metres; the pain goes away after she
More informationLong-Term Complications of Diabetes Mellitus Macrovascular Complication
Long-Term Complications of Diabetes Mellitus Macrovascular Complication Sung Hee Choi MD, PhD Professor, Seoul National University College of Medicine, SNUBH, Bundang Hospital Diabetes = CVD equivalent
More informationAssessing Cardiovascular Risk to Optimally Stratify Low- and Moderate- Risk Patients. Copyright. Not for Sale or Commercial Distribution
CLINICAL Viewpoint Assessing Cardiovascular Risk to Optimally Stratify Low- and Moderate- Risk Patients Copyright Not for Sale or Commercial Distribution By Ruth McPherson, MD, PhD, FRCPC Unauthorised
More informationAssociation between Raised Blood Pressure and Dysglycemia in Hong Kong Chinese
Diabetes Care Publish Ahead of Print, published online June 12, 2008 Raised Blood Pressure and Dysglycemia Association between Raised Blood Pressure and Dysglycemia in Hong Kong Chinese Bernard My Cheung,
More informationLow HDL-levels: leave it or treat it?
Cardiology Update 2011 Davos, 14 02 2011 Low HDL-levels: leave it or treat it? Experts: J.P. Kastelein, Amsterdam and U. Landmesser, Zurich Cases: C. Besler, Zurich and I. Sudano, Zurich Mr H.B., 1960
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Solomon SD, Uno H, Lewis EF, et al. Erythropoietic response
More informationPart 1 Risk Factors and Atherosclerosis. LO1. Define the Different Forms of CVD
Week 3: Cardiovascular Disease Learning Outcomes: 1. Define the difference forms of CVD 2. Describe the various risk factors of CVD 3. Describe atherosclerosis and its stages 4. Describe the role of oxidation,
More informationPatient referral for elective coronary angiography: challenging the current strategy
Patient referral for elective coronary angiography: challenging the current strategy M. Santos, A. Ferreira, A. P. Sousa, J. Brito, R. Calé, L. Raposo, P. Gonçalves, R. Teles, M. Almeida, M. Mendes Cardiology
More informationTHE EFFECT OF VITAMIN-C THERAPY ON HYPERGLYCEMIA, HYPERLIPIDEMIA AND NON HIGH DENSITY LIPOPROTEIN LEVEL IN TYPE 2 DIABETES
Int. J. LifeSc. Bt & Pharm. Res. 2013 Varikasuvu Seshadri Reddy et al., 2013 Review Article ISSN 2250-3137 www.ijlbpr.com Vol. 2, No. 1, January 2013 2013 IJLBPR. All Rights Reserved THE EFFECT OF VITAMIN-C
More informationThere are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk?
There are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk? Michael Davidson M.D. FACC, Diplomate of the American Board of Lipidology Professor,
More informationIsoprostanes: Biomarkers for Oxidative Stress
Isoprostanes: Biomarkers for Oxidative Stress Denis Callewaert, Ph.D. President, Oxford Biomedical Research, Inc. Professor Emeritus, Oakland University 2012 Oxford Biomedical Research, Inc. All rights
More informationTraitements associés chez l hypertendu: Statines, Aspirine
Traitements associés chez l hypertendu: Statines, Aspirine Pr Jean-Jacques Mourad CHU Avicenne, Université Paris 13, Bobigny DU HTA, Mars 2012 jean-jacques.mourad@avc.aphp.fr Global Mortality 2000: Impact
More informationLEPTIN AS A NOVEL PREDICTOR OF DEPRESSION IN PATIENTS WITH THE METABOLIC SYNDROME
LEPTIN AS A NOVEL PREDICTOR OF DEPRESSION IN PATIENTS WITH THE METABOLIC SYNDROME Diana A. Chirinos, Ronald Goldberg, Elias Querales-Mago, Miriam Gutt, Judith R. McCalla, Marc Gellman and Neil Schneiderman
More informationTreatment of Cardiovascular Risk Factors. Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center
Treatment of Cardiovascular Risk Factors Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center Disclosures: None Objectives What do risk factors tell us What to check and when Does treatment
More informationThe 10 th International & 15 th National Congress on Quality Improvement in Clinical Laboratories
The 10 th International & 15 th National Congress on Quality Improvement in Clinical Laboratories Cardiac biomarkers in atherosclerosis Najma Asadi MD-APCP Ross and Colleagues in 1973: Response to Injury
More informationImproved control for confounding using propensity scores and instrumental variables?
Improved control for confounding using propensity scores and instrumental variables? Dr. Olaf H.Klungel Dept. of Pharmacoepidemiology & Clinical Pharmacology, Utrecht Institute of Pharmaceutical Sciences
More informationNon alcoholic fatty liver disease and atherosclerosis Raul Santos, MD
Non alcoholic fatty liver disease and atherosclerosis Raul Santos, MD Sao Paulo Medical School Hospital Sao Paulo, Brazil Disclosure Honoraria received for consult and/or speaker : Astra Zeneca, Amgen,
More information